SCHEMBL7767768

SCHEMBL7767768

Fc1ccc(C(Cl)c2ccccn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.46
SLC6A2 P23975 5/20 0.46
SLC6A4 P31645 5/20 0.46
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CHRM2 P08172 3/20 0.38
TSHR P16473 3/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
ADRA2B P18089 2/20 0.38
HRH2 P25021 2/20 0.38
HTR2A P28223 2/20 0.38
HRH1 P35367 2/20 0.38
KCNH2 Q12809 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
CYP2C9 P11712 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA2A P08913 2/20 0.38
OPRK1 P41145 2/20 0.38
SCN1A P35498 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14033619 0.84 SLC6A2 (0.63) SLC6A3SLC6A2SLC6A4CHRM2TSHR
SCHEMBL14033203 0.83 SLC6A2 (0.53) SLC6A3SLC6A2SLC6A4CHRM2TSHR
Hydrochloric Acid SCHEMBL11199246 0.82 SLC6A2 (0.61) SLC6A3SLC6A2SLC6A4CHRM2TSHR
Hydrochloric Acid SCHEMBL20897391 0.81 SLC6A2 (0.51) SLC6A3SLC6A2SLC6A4CHRM2TSHR
SCHEMBL14621795 0.81 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MEN1KMT2A
SCHEMBL38664568 0.81 SLC6A2 (0.48) SLC6A3SLC6A2SLC6A4CHRM2TSHR
SCHEMBL6227535 0.80 SLC6A2 (0.54) SLC6A3SLC6A2SLC6A4MEN1KMT2A
SCHEMBL23610045 0.78 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4KMT2ATSHR
SCHEMBL17842469 0.78 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4KMT2ATSHR
SCHEMBL6775380 0.78 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233799-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2021-05-19 EP disclosed
EP-3233799-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2021-05-19 EP disclosed
US-10752588-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-08-25 US disclosed
US-10752588-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-08-25 US disclosed
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-11-14 US disclosed
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-11-14 US disclosed
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-01-24 US disclosed
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-01-24 US disclosed
EP-3233799-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 EP disclosed
WO-2016100823-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 WO disclosed
WO-2016100823-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 WO disclosed
EP-0690051-B1 DIAZACYCLOALKANEALKYLSULFONAMIDE DERIVATIVE AZWELL INC (JP) 2001-07-18 EP disclosed
US-5716950-A NONTOXIC ANTIALLERGEN AND ANTIASTHMATIC HAVING LOW ANTIHISTAMINIC SIDE EFFECTS NIPPON SHOJI KABUSHIKI KAISHA (JP) 1998-02-10 US disclosed
EP-0690051-A1 DIAZACYCLOALKANEALKYLSULFONAMIDE DERIVATIVE NIPPON SHOJI KABUSHIKI KAISHA (JP) 1996-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 SLC6A3 2/4885SLC6A2 14/4885SLC6A4 125/4885
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 SLC6A3 2/4885SLC6A2 14/4885SLC6A4 125/4885
US-10752588-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 SLC6A3 2/4885SLC6A2 14/4885SLC6A4 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.